Old Mission Capital’s Celldex Therapeutics CLDX Stock Holding History

Old Mission Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,663	Closed	-$837K	–	1379
2021 Q4	$837K	Buy	+21,663	New	+$944K	0.03%	482
2021 Q1	–	Sell	-22,403	Closed	-$392K	–	741
2020 Q4	$392K	Buy	+22,403	New	+$403K	0.02%	398

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Old Mission Capital's CLDX Position: Q1 2022 in Review

Old Mission Capital sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 21,663 shares — an estimated $837K sold.

Old Mission Capital first reported a position in CLDX in Q4 2020 and held it in 2 quarters. The position peaked at $837K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Old Mission Capital reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
Old Mission Capital sold 21,663 Celldex Therapeutics shares in Q1 2022, an estimated $837K.
Old Mission Capital first reported a position in Celldex Therapeutics in Q4 2020 and held it in 2 quarters.
Old Mission Capital's Celldex Therapeutics position peaked at $837K in Q4 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Old Mission Capital's 13F filing for Q1 2022, filed 13 May 2022.